We recommend that all patients with AIDS-defining malignancies should start HAART .

We suggest that all patients with non-AIDS-defining malignancies who are due to start chemotherapy or radiotherapy should be started on HAART unless contraindicated .

We recommend that prophylaxis against Pneumocystis jirovecii pneumonia (PCP) should be started for those who have a CD4 cell count less than 200 cells/μL and should be considered at higher levels in all patients starting chemotherapy or radiotherapy.

We recommend prophylaxis against MAC for individuals with a CD4 cell count less than 50 cells/μL and in those whose treatment puts their CD4 count at risk of falling below this level.

We recommend that systemic azole antifungal prophylaxis should be used in all patients receiving chemotherapychemotherapy or radiotherapy for HIV-associated malignancy.

We do not recommend routine fluoroquinolone prophylaxis in low-risk patients and the use of cotrimoxazole to prevent PCP may provide some protection against bacterial infection for patients living with HIV .

We recommend HSV prophylaxis in people living with HIV with a history of HSV infection who are starting

chemotherapy to reduce the incidence and severity of reactivations .

We recommend annual influenza vaccination .

We recommend vaccination against pneumococcus and hepatitis B virus .

We recommend that patients with antibodies against hepatitis B core antigen (HBcAb) should be treated with prophylactic antivirals in line with BHIVA hepatitis guidelines